Anti-TNF-alpha therapy for acute rejection in intestinal transplantation |
| |
Authors: | Pascher A Klupp J Langrehr J M Neuhaus P |
| |
Institution: | Department of General and Transplantation Surgery, Charité, Campus Virchow Clinic, Berlin, Germany. andreas.pascher@charite.de |
| |
Abstract: | INTRODUCTION: We present our experience with infliximab rescue therapy for steroid- and OKT3-resistant rejection after intestinal transplantation (ITx). METHODS: Twelve ITx and one multivisceral transplant recipients were immunosuppressed with tacrolimus, rapamycin, daclizumab, steroids (n = 10) or tacrolimus, campath, and steroids (n = 3). RESULTS: In two patients, severe acute rejection did not resolve despite steroid bolus therapy plus 5 to 10 days of OKT3 treatment. Signs of moderate rejection persisted in the distal portions of the grafts. Treatment with infliximab, a chimeric anti-TNF-alpha antibody (four infusions of 3 mg/kg body weight), induced a complete remission of histological and clinical signs of rejection. Two further patients with steroid-resistant rejection received two courses of infliximab (3 mg/kg body weight) as antirejection therapy. All rejection episodes resolved completely. CONCLUSIONS: Infliximab effectively treats steroid and OKT3 resistant acute rejection episodes of intestinal transplantations. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|